| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-12-2426 |
| P8608 | Fatcat ID | release_gwdqqk736ncena7h7hm7fb2jca |
| P932 | PMC publication ID | 3640274 |
| P698 | PubMed publication ID | 23444227 |
| P50 | author | Soldano Ferrone | Q90626068 |
| Robert L Ferris | Q38328358 | ||
| P2093 | author name string | William E Gooding | |
| Pedro A Andrade Filho | |||
| Raghvendra M Srivastava | |||
| Hyun-Bae Jie | |||
| Sandra P Gibson | |||
| H Carter Davidson | |||
| Andrés López-Albaitero | |||
| Steve C Lee | |||
| Christopher A Lord | |||
| P2860 | cites work | Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 |
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity | Q34073138 | ||
| Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape | Q34194706 | ||
| Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer | Q34477841 | ||
| Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction | Q73709048 | ||
| FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab | Q80667395 | ||
| Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy | Q81038993 | ||
| Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma | Q81461355 | ||
| Immune complex-mediated antigen presentation induces tumor immunity | Q34793164 | ||
| IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells | Q34798580 | ||
| EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma | Q35416013 | ||
| Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer | Q35432484 | ||
| Helper role of NK cells during the induction of anticancer responses by dendritic cells | Q35988425 | ||
| Natural-killer cells and dendritic cells: "l'union fait la force". | Q36149272 | ||
| IL-18-induced CD83+CCR7+ NK helper cells | Q36403560 | ||
| Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer | Q36526586 | ||
| Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. | Q36532521 | ||
| Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. | Q36741216 | ||
| Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients | Q36962838 | ||
| Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer | Q37126351 | ||
| Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer | Q37369840 | ||
| Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies | Q37393024 | ||
| Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy | Q37729135 | ||
| The future of anti-CD20 monoclonal antibodies: are we making progress? | Q37826312 | ||
| The bidirectional crosstalk between human dendritic cells and natural killer cells | Q37853782 | ||
| The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions? | Q37993188 | ||
| Combining immunotherapy and targeted therapies in cancer treatment | Q37995939 | ||
| IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab | Q39617025 | ||
| Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response | Q39707969 | ||
| Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function | Q39824406 | ||
| Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells | Q39868562 | ||
| Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 | ||
| Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer | Q40034263 | ||
| The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines | Q40061963 | ||
| Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells | Q40333010 | ||
| Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. | Q40500501 | ||
| FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia | Q40500947 | ||
| Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma | Q40562102 | ||
| Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses | Q40848632 | ||
| Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. | Q41977456 | ||
| Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function | Q43442797 | ||
| FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia | Q44620749 | ||
| Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype | Q45105839 | ||
| FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. | Q45949257 | ||
| Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. | Q46151045 | ||
| Head and neck cancer | Q54152939 | ||
| Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage | Q56908749 | ||
| Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 | Q62604205 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cetuximab | Q420296 |
| dendritic cell | Q506253 | ||
| head and neck cancer | Q1783924 | ||
| collaboration | Q1145523 | ||
| head and neck carcinoma | Q18554836 | ||
| neck cancer | Q18966654 | ||
| P304 | page(s) | 1858-1872 | |
| P577 | publication date | 2013-02-26 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients | |
| P478 | volume | 19 |
| Q28079622 | 4-1BB agonism: adding the accelerator to cancer immunotherapy |
| Q42344612 | A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs |
| Q37138274 | A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. |
| Q47117489 | A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma |
| Q92188218 | A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab |
| Q38258842 | Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy |
| Q38808823 | Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer |
| Q27000706 | Advances in the understanding of cancer immunotherapy |
| Q41549486 | Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis |
| Q38880179 | An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions |
| Q39231967 | An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma |
| Q40471529 | Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. |
| Q26774312 | Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches |
| Q36539682 | Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells |
| Q47722599 | Antitumor Antibodies Can Drive Therapeutic T Cell Responses |
| Q38944242 | Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid |
| Q57191726 | Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells |
| Q38389321 | Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective |
| Q39190801 | Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma |
| Q64250623 | CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy |
| Q50043038 | CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer |
| Q41808416 | CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies |
| Q92718871 | CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γc cytokine stimulation via PI3K/mTOR axis |
| Q35674757 | CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis |
| Q27329648 | Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids |
| Q52893935 | Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. |
| Q36286498 | Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients |
| Q37204600 | Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model |
| Q38868396 | Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers |
| Q35149637 | Classification of current anticancer immunotherapies |
| Q55617875 | Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. |
| Q64116258 | Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer |
| Q64078973 | Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma |
| Q35940189 | Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity |
| Q52606685 | Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. |
| Q59477539 | Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations |
| Q37563581 | Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need |
| Q92203387 | Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells |
| Q90734623 | Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors |
| Q58740344 | Drug resistance and new therapies in colorectal cancer |
| Q30835988 | EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex |
| Q92538826 | Editorial: Lymphocyte Functional Crosstalk and Regulation |
| Q38693634 | Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen |
| Q89522931 | Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies |
| Q38841850 | Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab. |
| Q91684535 | Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies |
| Q33607015 | FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance |
| Q53511600 | Fc-Gamma receptor polymorphism and gene expression of peripheral blood mononuclear cells in patients with HER2-positive metastatic breast cancer receiving single-agent trastuzumab. |
| Q38650710 | Head and Neck Carcinoma Immunotherapy: Facts and Hopes |
| Q35839942 | High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma |
| Q57729450 | Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells |
| Q36642668 | Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer |
| Q55380684 | Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. |
| Q58694216 | Immune Checkpoint Inhibition in Head and Neck Cancer |
| Q91983062 | Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics |
| Q28069424 | Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment |
| Q34723594 | Immune biomarkers of anti-EGFR monoclonal antibody therapy |
| Q26765115 | Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials |
| Q92092322 | Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma |
| Q28079180 | Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies |
| Q37605030 | Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells |
| Q36100837 | Immunology and Immunotherapy of Head and Neck Cancer |
| Q53111596 | Immunotherapy for Colorectal Cancer. |
| Q87861147 | Immunotherapy for Head and Neck Squamous Cell Carcinoma |
| Q45998119 | Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. |
| Q60931068 | Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment |
| Q38601426 | Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus? |
| Q28087719 | Improving natural killer cell cancer immunotherapy |
| Q90705224 | In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea? |
| Q52776942 | Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. |
| Q49017289 | Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck |
| Q38162129 | Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer |
| Q41482113 | Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q64290298 | Knowing the tumour microenvironment to optimise immunotherapy |
| Q41909644 | Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a preclinical model |
| Q90478443 | Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab |
| Q59804801 | Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors |
| Q92034605 | Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy |
| Q26797345 | NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy |
| Q102057122 | NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis |
| Q34933101 | NK cells and T cells cooperate during the clinical course of colorectal cancer |
| Q55407980 | Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies. |
| Q33809528 | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients |
| Q97532341 | Novel Immunotherapeutic Approaches in Head and Neck Cancer |
| Q37473163 | Novel anti-EPHA2 antibody, DS-8895a for cancer treatment |
| Q39139069 | Oncogenic growth factor signaling mediating tumor escape from cellular immunity |
| Q27025600 | Oncolytic viruses as anticancer vaccines |
| Q57035027 | PD-L1 mediates dysfunction in activated PD-1+ NK cells in head and neck cancer patients |
| Q61812354 | Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma |
| Q47735681 | Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals |
| Q33900573 | Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805. |
| Q52591781 | Precision Therapy of Head and Neck Squamous Cell Carcinoma. |
| Q47704805 | Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms. |
| Q93173226 | Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients |
| Q94465295 | Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy |
| Q36115580 | Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy |
| Q37022365 | Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab |
| Q36883848 | Promising systemic immunotherapies in head and neck squamous cell carcinoma |
| Q36412214 | Quantification of anti-sperm antibody and soluble MICA/MICB levels in the serum of infertile people of the Li ethnic group in China |
| Q59606033 | Radiotherapy plus EGFR inhibitors: synergistic modalities. |
| Q46113809 | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation |
| Q37171499 | Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage. |
| Q41996352 | Roles for Innate Immunity in Combination Immunotherapies |
| Q35920773 | STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients |
| Q52678799 | STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. |
| Q58129612 | T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response |
| Q37028027 | TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. |
| Q39150078 | TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells |
| Q35087551 | Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma |
| Q35623980 | Tailored immunotherapy for HPV positive head and neck squamous cell cancer |
| Q47350013 | Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer |
| Q49961144 | Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma |
| Q90133295 | Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments |
| Q33872482 | Targeting CD137 enhances the efficacy of cetuximab. |
| Q38838071 | Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. |
| Q38383212 | The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial |
| Q36535465 | The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies |
| Q64947969 | The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective. |
| Q38183569 | The immune system and response to HER2-targeted treatment in breast cancer |
| Q40129971 | The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. |
| Q59469171 | The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. |
| Q37652790 | Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy |
| Q26993238 | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy |
| Q42867339 | Trial watch: Dendritic cell-based interventions for cancer therapy |
| Q42558833 | Trial watch: Tumor-targeting monoclonal antibodies for oncological indications |
| Q27009908 | Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity |
| Q90176787 | Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? |
| Q35025009 | Unraveling the molecular genetics of head and neck cancer through genome-wide approaches |
| Q43119856 | Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab. |
| Q58110501 | Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits |
| Q34049613 | mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations |
Search more.